Navigation
此类别记录
- 易瑞沙(IRESSA)中文说明
- 易瑞沙使用总结
- 吉非替尼治疗晚期肺癌一年生存率可达30%
- 易瑞沙耐药后再次使用仍可能有效
- ZD1839 易瑞沙(吉非替尼)的基础研究
- 特罗凯(Tarceva)中文说明书
- 力比泰(ALIMTA)中文说明书
- 索坦(舒尼替尼)中文说明书
- 秘鲁特罗凯怎么样
- 易瑞沙耐药后该怎么办!
- 印度特罗凯重新出山
- 靶向药物更适合非吸烟所致肺癌
- 印度易瑞沙真假辨别方法
- 泰欣生是什么
- 索拉非尼(多吉美)是什么
- 什么是二代易瑞沙
- 格列卫(Glivec)是什么
- 舒尼替尼(索坦)是什么
- 不是所有人都能靶向
- 还能代购吗?
- 易瑞沙肺纤维化治疗
- 培美曲塞二钠是什么
- 易瑞沙耐药后的治疗方法
- 最近小心假易瑞沙及特罗凯
- 肺癌靶向药耐药基因被找到
- 安体舒是什么(靶向)
- 新疫苗让肺癌不复发
- 尼罗替尼(Tasigna)中文说明书
- 易瑞沙申请免费赠药方式
- 看靶向药适合您吗?
- 瑞辉肺癌新药Sutent失败
- 希罗达是什么靶向药
- 易瑞沙最新包装与旧包装对比照(图)
- 新靶向药盐酸埃克替尼(克美纳)三期临床
- 易瑞沙联合复方丹参滴丸及洛伐他汀抗耐药
- 靶向药前做EGFR突变检测更准确
- BIBW2992肺癌又一新药
- 关于印度易瑞沙去除NEW PACK字样及底部开胶现象
- 易瑞沙耐药后的又一选择印度多吉美
- 什么样的肺癌病人用靶向药最有效
- 无疾病存活期较化疗长
- 胆囊癌可以尝试使用易瑞沙
- 美国FDA批准非小细胞肺癌药物Xalkori上市
- 本站泰道到货实拍
- 案值三亿的“印度易瑞沙”案
- 新NATCO产印度多吉美到货
Tags
印度易瑞沙 印度特罗凯 印度力比泰 印度多吉美 等肺癌交流群
官方QQ群1:26438631 群2:5100806 www.feiai88.com!
肺癌靶向药物
ID #1050
靶向药物更适合非吸烟所致肺癌
在全球第九个“国际肺癌关注月”来临之际,“‘易’分钟行动”的倡导者、首都医科大学肺癌诊疗中心主任支修益教授发出呼吁,号召更多肺癌临床医务工作者参与“‘易’分钟行动”,进行肺癌防治知识的科普宣传,争取让病人获取更长的生存时间和更好的生活质量。
我国首个以肺癌防治专家为主体、以医患沟通为主题的科普宣教项目“直击肺癌——‘易’分钟行动”,自2009年4月份启动以来,已陆续在全国8个城市开展,引起了相关专家及肺癌患者的强烈关注和共鸣。
北京协和医院胸外科主任李单青教授表示:“在癌症发生机制上,吸烟所致肺癌多走‘K-ras途径’,多为鳞癌、小细胞癌;非吸烟所致肺癌则多走‘人体表皮生长因子受体途径’,多为非小细胞肺癌。走该路的肺癌对化疗药物不敏感,化疗有效率只有30%至40%,目前尚无很有效的靶向治疗药物;而走人体表皮生长因子受体这条路的肺癌除了化疗,还有相当有效的靶向治疗药物。”
一项临床试验结果表明,发生人体表皮生长因子受体基因突变的肺癌患者对靶向药物如易瑞沙等高度敏感,而且,亚裔非小细胞肺癌患者人体表皮生长因子受体突变的发生率为30%至40%,高于欧洲的10%至15%。发生基因突变的晚期非小细胞肺癌患者可在被诊断初期就选用特异靶向药物治疗。
==== 汉译英 ====
Ninth in the world "International concerns on lung cancer," the dawn, " 'easy' minute action" advocates, Capital University of Medical Director of the Center of lung cancer treatment, Professor Zhi Xiuyi appeal, calling for more medical workers involved in lung cancer, " 'Easy' minutes of action, "for lung cancer prevention and control knowledge of science, enlisting the patient to obtain a longer survival time and a better quality of life.
China's first lung cancer prevention and treatment expert as the main body to the theme of the popular doctor-patient communication missionary project "Zhi Ji lung cancer - 'Easy' minutes of action", since inception in April 2009, has started eight cities across the country, rise to the relevant experts and lung cancer in patients with a strong focus and resonance.
Beijing Union Medical College Hospital, director of thoracic surgery Professor Li Danqing, said: "In the cancer mechanism that smoking caused lung cancer, go 'K-ras approach', mostly for squamous cell carcinoma, small cell carcinoma; non-smoking caused lung cancer is go 'the human epidermal growth factor receptor pathway', many non-small cell lung cancer. walk the road of lung cancer is not sensitive to chemotherapy drugs, chemotherapy, only 30% efficiency to 40%, at present there is no very effective targeted therapy ; while walking human epidermal growth factor receptor on this road apart from chemotherapy of lung cancer, there are quite effective targeted therapy drugs. "
A clinical trial results show that the occurrence of human epidermal growth factor-receptor gene mutations in lung cancer patients to targeted drugs such as Iressa and other highly sensitive, and that Asian patients with non-small cell lung cancer of human Epidermal Growth Factor Receptor Mutation in the incidence of 30% to 40% higher than the European 10% to 15%. Which genetic mutations in patients with advanced non-small cell lung cancer was diagnosed in early stage on the selection of target-specific drug treatment.
China's first lung cancer prevention and treatment expert as the main body to the theme of the popular doctor-patient communication missionary project "Zhi Ji lung cancer - 'Easy' minutes of action", since inception in April 2009, has started eight cities across the country, rise to the relevant experts and lung cancer in patients with a strong focus and resonance.
Beijing Union Medical College Hospital, director of thoracic surgery Professor Li Danqing, said: "In the cancer mechanism that smoking caused lung cancer, go 'K-ras approach', mostly for squamous cell carcinoma, small cell carcinoma; non-smoking caused lung cancer is go 'the human epidermal growth factor receptor pathway', many non-small cell lung cancer. walk the road of lung cancer is not sensitive to chemotherapy drugs, chemotherapy, only 30% efficiency to 40%, at present there is no very effective targeted therapy ; while walking human epidermal growth factor receptor on this road apart from chemotherapy of lung cancer, there are quite effective targeted therapy drugs. "
A clinical trial results show that the occurrence of human epidermal growth factor-receptor gene mutations in lung cancer patients to targeted drugs such as Iressa and other highly sensitive, and that Asian patients with non-small cell lung cancer of human Epidermal Growth Factor Receptor Mutation in the incidence of 30% to 40% higher than the European 10% to 15%. Which genetic mutations in patients with advanced non-small cell lung cancer was diagnosed in early stage on the selection of target-specific drug treatment.
Tags: 靶向药物非吸烟
相关条目: -
更新日期: 2009-11-15 03:23
作者: : mcyclub
修订: 1.0
你不能对该内容发表评论